A Unique Chimeric RNA: ERCC1‐iASPP Drives Benzo[a]pyrene‐Induced Lung Carcinogenesis via Dual Coding and Non‐Coding Mechanisms
Genetic variation at 19q13.3 critically modulates chemical carcinogen-induced lung carcinogenesis, particularly in mediating the activity of benzo[a]pyrene (B[a]P), a major polycyclic aromatic hydrocarbon (PAH) carcinogen. The adjacent genes ERCC1 and iASPP within this locus respectively coordinate nucleotide excision repair of PAH-induced DNA damage and suppression of apoptotic pathways. Their synergistic interaction regulates pivotal molecular events during PAH-driven lung carcinogenesis, ultimately impacting cellular repair, proliferation, and apoptosis. Chimeric RNAs have been increasingly recognized as promising biomarkers and therapeutic targets in cancer. However, the characterization of lung cancer-specific chimeric RNAs in the context of chemical carcinogenesis remains limited. This study identifies and characterizes ERCC1-iASPP, a novel chimeric RNA derived from the neighboring genes ERCC1 and iASPP, which exerts tumor-promoting functions via coding and non-coding mechanisms. First, the chimeric transcript encodes a previously uncharacterized protein, Ei, which enhances USP45-mediated deubiquitination of ERCC1, thereby stabilizing ERCC1 protein. Additionally, ERCC1-iASPP also functions as a (long non-coding chimeric RNA, lnccRNA): in the cytoplasm, it acts as a (competing endogenous RNA, ceRNA) by sequestering miR-143-3p, leading to derepression of CDK1 and PGK1 and subsequent activation of oncogenic pathways, while in the nucleus, ERCC1-iASPP further promotes transcriptional activation by recruiting STAT4 to the PGK1 promoter. Collectively, these findings establish ERCC1-iASPP as a bifunctional RNA with both protein-coding and non-coding regulatory roles that cooperatively promote B[a]P-induced lung tumorigenesis. This study highlights ERCC1-iASPP as a potential diagnostic and therapeutic target in smoking-related lung cancer.
Authors
- Guopei Zhang (ORCID: https://orcid.org/0000-0003-4541-914X)
- Xiaobo Lu (ORCID: https://orcid.org/0000-0002-3136-9439)
- Yujin Li (ORCID: https://orcid.org/0000-0003-1103-3273)
- Mingyang Xiao (ORCID: https://orcid.org/0000-0003-0365-4133)
- Mingming Shan (ORCID: https://orcid.org/0000-0002-0437-6414)
- Shen Wang (ORCID: https://orcid.org/0000-0003-3076-0572)
- Liang Zhang (ORCID: https://orcid.org/0000-0002-7672-1168)
- Jihong Wu
- Junwei Xie (ORCID: https://orcid.org/0009-0004-2906-3838)
- Kang Cao
Institutions
- Shenyang Center for Disease Control and Prevention (CN)
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1002/advs.202507217
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00